Abstract Summary
Objective
To determine whether ashwagandha (Withania somnifera) benefits skin health through clinical and mechanistic evidence.
Context
Ashwagandha is an Ayurvedic adaptogen used for over 3,000 years. Its anti-inflammatory and cortisol-lowering properties have sparked growing clinical interest in dermatological applications, including skin aging, barrier repair, and inflammatory skin conditions.
Methods Used
Approach
Narrative review of randomized controlled trials, in vitro keratinocyte studies, and in vivo models evaluating topical and oral ashwagandha.
Data Collection
Data were sourced from PubMed, PubMed Central, Scopus, and Google Scholar using search terms including Withania somnifera, ashwagandha, withanolides, skin aging, dermatology, wound healing, and anti-inflammatory. Peer-reviewed articles, conference proceedings from SKIN The Journal of Cutaneous Medicine (Vol. 9, July 2025), and pharmacological databases were consulted. Studies with standardized extract formulations, defined withanolide content, and placebo-controlled designs were prioritized.
Researchers' Summary of Findings
Health Implications
Ashwagandha shows a strong safety profile for topical use across skin types. Oral use is safe for healthy adults but should be avoided in pregnancy, liver disease, and autoimmune conditions. Larger trials are needed before clinical guidelines can be issued.
Impact on Health
A 2023 double-blind RCT (Narra et al., Cureus) applied 8% ashwagandha lotion to 56 photoaged adults for 60 days, yielding a 74.69% reduction in physician scores versus 48.68% placebo. Key improvements: hydration +20.66%, skin elasticity +16.34%, TEWL −15.12%, wrinkles −55.9%, pigmentation −80.5%. Adverse events were mild and comparable to placebo.
Sustainability
Withania somnifera is drought-tolerant and pesticide-light. Aqueous extraction minimizes waste. Standardized withanolide content and accurate labeling are essential for responsible use.
DOI
10.7759/cureus.36168
